The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies

European Psychiatry

Volumn 30, Issue 4, 2015, Pages 511-520

  Asherson, P ^a   Stes, S ^b,c   Nilsson Markhed, M ^d   Berggren, L ^e   Svanborg, P ^f   Kutzelnigg, A ^g   Deberdt, W ^h  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Thomas More University College   (Belgium)

^d UPPSALA UNIVERSITY   (Sweden)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f ELI LILLY AND COMPANY   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h Eli Lilly Benelux   (Belgium)

Author keywords

ADHD; Atomoxetine; Emotional control; Integrated analysis

Indexed keywords

ATOMOXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; DRUG EFFECT; DRUG EFFICACY; DSM-IV; EFFECT SIZE; EMOTION; EMOTIONAL CONTROL; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; TREATMENT RESPONSE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATOMOXETINE HYDROCHLORIDE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84930869734     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.12.002     Document Type: Article

References (54)

1. Adler L.A., Spencer T.J., Williams D.W., Moore R.J., Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008, 12(3):248-253. [PubMed: 18448861].
2. Adler L.A., Clemow D.B., Williams D.W., Durell T.M. Atomoxetine effects on executive function as measured by the BRIEF--A in young adults with ADHD: a randomized, double-blind, placebo-controlled study. PLoS One 2014, 9(8):e104175. [PubMed: 25148243].
3. Adler L., Tanaka Y., Williams D., Trzepacz P.T., Goto T., Allen A.J., et al. Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. J Clin Psychopharmacol 2014, 34(4):461-466. [PubMed: 24977716].
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Text Revision (DSM-IV-TR) 2000, American Psychiatric Press, Washington DC. 4th ed.
5. American Psychiatric Association Diagnostic Statistical Manual of Mental Disorders (DSM-III) 1980, American Psychiatric Press, Washington DC. 3rd ed.
6. American Psychiatric Association Diagnostic Statistical Manual of Mental Disorders (DSM-5) 2013, American Psychiatric Press, Washington DC. 5th ed.
7. Anastopoulos A.D., Smith T.F., Garrett M.E., Morrissey-Kane E., Schatz N.K., Sommer J.L., et al. Self-regulation of emotion, functional impairment, and comorbidity among children with AD/HD. J Atten Disord 2011, 15(7):583-592. [PubMed: 20686097].
8. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 2005, 5(4):525-539. [PubMed: 16026236].
9. Asherson P., Bushe C., Saylor K., Tanaka Y., Deberdt W., Upadhyaya H.J. Psychopharmacol. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol 2014, 28(9):837-846. [PubMed: 25035246].
10. Banaschewski T., Jennen-Steinmetz C., Brandeis D., Buitelaar J.K., Kuntsi J., Poustka L., et al. Neurpsychological correlates of emtional lability in children with ADHD. J Child Psychol Psychiatry 2012, 53(11):1139-1148. [PubMed: 22882111].
11. Barkley R.A. Deficient emotional self-regulation: a core component of attention-deficit/hyperactivity disorder. J ADHD Relat Disord 2010, 1(2):5-37.
12. Barkley R.A., Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry 2010, 49(5):503-513. [PubMed: 20431470].
13. Barkley R.A., Murphy K.R. Deficient emotional self-regulation in adults with attention-deficit/hyperactivity disorder (ADHD): the relative contributions of emotional impulsiveness and ADHD symptoms to adaptive impairments in major life activities. J ADHD Relat Disord 2010, 1(4):5-28.
14. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937, 94:577-585.
15. Brod M., Johnston J., Able S., Swindle R. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res 2006, 15(1):117-129. [PubMed: 16411036].
16. Brown T.E., Holdnack J., Saylor K., Adler L., Spencer T., Williams D.W., et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord 2011, 15(2):130-138. [PubMed: 20026871].
17. Conners C.K., Erhardt D., Sparrow E. Conners' Adult A.D.H.D. Rating Scales (CAARS) 1999, Multi-Health Systems Inc, North Tonawanda NY.
18. Durell T.M., Pumariega A.J., Rothe E.M., Tamayo J.M., Baron D., Williams D. Effects of open-label atomoxetine on African-American and Caucasian pediatric outpatients with attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 2009, 21(1):26-37. [PubMed: 19239830].
19. Durell T.M., Adler L.A., Williams D.W., Deldar A., McGough J.J., Glaser P.E., et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2013, 33(1):45-54. [PubMed: 23277268].
20. Epstein J.N., Conners C.K., Erhardt D., Arnold L.E., Hechtman L., Hinshaw S.P., et al. Familial aggregation of ADHD characteristics. J Abnorm Child Psychol 2000, 28(6):585-594. [PubMed: 11104319].
21. Faraone S.V., Spencer T., Aleardi M., Pagano C., Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004, 24(1):24-29. [PubMed: 14709943].
22. Faraone S.V., Biederman J., Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006, 36(2):159-165. [PubMed: 16420712].
23. Fayyad J., De Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K., et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007, 190:402-409. [PubMed: 17470954].
24. Ferrer M., Andión O., Matalí J., Valero S., Navarro J.A., Ramos-Quiroga J.A., et al. Comorbid attention-deficit/hyperactivity disorder in borderline patients defines an impulsive subtype of borderline personality disorder. J Pers Disord 2010, 24(6):812-822. [PubMed: 21158602].
25. Goto T., Hirata Y., Takita Y., Trzepacz P.T., Allen A.J., Song D.H., et al. Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: a multinational 10-week randomized double-blind placebo-controlled Asian study. J Atten Disord 2013, [Epub ahead of print, PubMed: 24203774].
26. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised 1976. 1976, 217-222. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD, [313-31].
27. Hoffman L.B. Postencephalitic behavior disorders in children. Bull Johns Hopkins Hosp 1922, 33:372-375.
28. Hulvershorn L.A., Mennes M., Castellanos F.X., Di Martino A., Milham M.P., Hummer T.A., et al. Abnormal amygdala functional connectivity associated with emotional lability in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2014, 53(3):351-361. [PubMed: 24565362].
29. Jarratt K.P., Riccio C.A., Siekierski B.M. Assessment of attention deficit hyperactivity disorder (ADHD) using the BASC and BRIEF. Appl Neuropsychol 2005, 12(2):83-93. [PubMed: 16083397].
30. Kessler R.C., Adler L., Barkley R., Biederman J., Conners C.K., Demler O., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723. [PubMed: 16585449].
31. Koesters M., Becker T., Kilian R., Fegert J.M., Weinmann S. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009, 23(7):733-744. [PubMed: 18562416].
32. Marchant B.K., Reimherr F.W., Halls C., Williams E.D., Strong R.E., Kondo D., et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Atten Defic Hyperact Disord 2011, 3(3):237-244. [PubMed: 21442440].
33. McIntyre R.S., Kennedy S.H., Soczynska J.K., Nguyen H.T., Bilkey T.S., Woldeyohannes H.O., et al. Attention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative project. Prim Care Companion J Clin Psychiatry 2010, 12(3.). [PubMed: 20944770].
34. Merwood A. Exploring the aetiology of ADHD: rater effects, the comorbidity with temperament and emotional lability, and polygenic scores 2013, [PhD thesis], King's College, London.
35. Merwood A., Chen W., Rijsdijk F., Skirrow C., Larsson H., Thapar A., et al. Genetic associations between the symptoms of attention-deficit/hyperactivity disorder and emotional lability in child and adolescent twins. J Am Acad Child Adolesc Psychiatry 2014, 53(2):209-220. [PubMed: 24472255].
36. Reimherr F.W., Marchant B.K., Strong R.E., Hedges D.W., Adler L., Spencer T.J., et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005, 58(2):125-131. [PubMed: 16038683].
37. Reimherr F.W., Williams E.D., Strong R.E., Mestas R., Soni P., Marchant BK: A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007, 68:93-101.
38. Reimherr F.W., Marchant B.K., Olsen J.L., Halls C., Kondo D.G., Williams E.D., et al. Emotional dysregulation as a core feature of adult ADHD: its relationship with clinical variables and treatment response in two methylphenidate trials. J ADHD Relat Disord 2010, 1(4):53-64.
39. Retz W., Stieglitz R.D., Corbisiero S., Retz-Junginger P., Rösler M. Emotional dysregulation in adult ADHD: What is the empirical evidence?. Expert Rev Neurother 2012, 12(10):1241-1251. [PubMed: 23082740].
40. Rösler M., Retz W., Fischer R., Ose C., Alm B., Deckert J., et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 2010, 11(5):709-718. [PubMed: 20353312].
41. ®-A) 2005, PAR Inc., Lutz, Florida.
42. Shaw P., Stringaris A., Nigg J., Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry 2014, 171(3):276-293. [PubMed: 24480998].
43. Simon V., Czobor P., Bálint S., Mészáros A., Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009, 194(3):204-211. [PubMed: 19252145].
44. Skirrow C., Asherson P. Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord 2013, 147(1-3):80-86. [PubMed: 23218897].
45. Skirrow C., Hosang G.M., Farmer A.E., Asherson P. An update on the debated association between ADHD and bipolar disorder across the lifespan. J Affect Disord 2012, 141(2-3):143-159. [PubMed: 22633181].
46. Skirrow C., McLoughlin G., Kuntsi J., Asherson P. Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. Expert Rev Neurother 2014, 9(4):489-503. [PubMed: 19344301].
47. Sobanski E., Sabljic D., Alm B., Baehr C., Dittmann R.W., Skopp G., et al. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 2012, 45(3):100-107. [PubMed: 22174029].
48. Still G.F. Some abnormal psychical conditions in children. Lancet 1902, 1:1008-1012. 1077-82, 1163-8].
49. Surman C.B., Biederman J., Spencer T., Yorks D., Miller C.A., Petty C.R., et al. Deficient emotional self-regulation adult attention deficit hyperactivity disorder: a family risk analysis. Am J Psychiatry 2011, 168(6):617-623. [PubMed: 21498464].
50. Surman C.B., Biederman J., Spencer T., Miller C.A., McDermott K.M., Faraone S.V. Understanding deficient emotional self-regulation in adults with attention deficit hyperactivity disorder: a controlled study. Atten Defic Hyperact Disord 2013, 5(3):273-281. [PubMed: 23413201].
51. Takahashi M., Goto T., Takita Y., Chung S.K., Wang Y., Gau S.S. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. Asia Pac Psychiatry 2014, 6(1):62-70. [PubMed: 23857916].
52. Tamayo J.M., Pumariega A., Rothe E.M., Kelsey D., Allen A.J., Vélez-Borrás J., et al. Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008, 18(1):44-53. [PubMed: 18294088].
53. Upadhyaya H., Adler L.A., Casas M., Kutzelnigg A., Williams D., Tanaka Y., et al. Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine. Child Adolesc Psychiatry Ment Health 2013, 7(1):14. [PubMed: 23648011].
54. Wingo A.P., Ghaemi S.N. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. J Clin Psychiatry 2007, 68(11):1776-1784. [PubMed: 18052572].